Vinorelbine Plus Apatinib Versus Vinorelbine in Advanced Triple-Negative Breast Cancer

NCT03254654 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

66

Enrollment

OTHER

Sponsor class

Conditions

Advanced Triple-Negative Breast Cancer

Interventions

DRUG: Vinorelbine
DRUG: Apatinib

Sponsor

Fudan University